Shareholders approve Strategy and Agreement of Merger with Ebix A.

This vote exceeded the required threshold, that was approval by a majority vote of the exceptional shares. Of the shares voted, over 99 % voted and only the merger. Under the conditions of the merger agreement, at the closing of the merger, each talk about of common share of A.D.A.M. Will be converted into the right to receive 0.3122 shares of common stock of Ebix. A.D.A.M. Has adequate cash on hand to meet the minimum amount requirements of the merger agreement, so no price adjustment to the exchange ratio is essential. Pursuant to the terms of the merger contract, the merger will occur within three business days after satisfaction of all the conditions to the merger.Eligible patients underwent randomization in a 2:1 ratio of active treatment to placebo, stratified according to clinical center. Both research and participants staff were unacquainted with the treatment assignments. However, medical blinding was difficult because of the infusion reactions that predominated in the rituximab group. The protocol and consent paperwork were approved by an unbiased ethics committee or institutional review board at each participating center. All sufferers offered written informed consent; patients under 18 years provided written assent. An unbiased data and security monitoring board met every six months and conducted quarterly overview safety reviews. A TrialNet medical monitor reviewed all adverse events.